← back to search

Yoav H. Messinger

Minnesota West Community & Technical College · US
Area of research
Surgery · Public Health, Environmental and Occupational Health
Research interest
Research interests include Congenital Diaphragmatic Hernia Studies, Acute Lymphoblastic Leukemia research, Tracheal and airway disorders, and Childhood Cancer Survivors' Quality of Life.
h-index
42
citations
7,130
works
177
NIH funding
primary concept
Medicine
email

Recent publications

Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study
The Lancet Haematology 2026cited by 0position: middledoi
Bloodstream Infections in Childhood Acute Myeloid Leukemia and Machine Learning Models: A Single-institutional Analysis.
2025cited by 2position: contributordoi
Prognostic Significance of Germline <i>DICER1</i> Pathogenic or Likely Pathogenic Variants in Outcomes of Ovarian Sertoli-Leydig Cell Tumor.
2025cited by 2position: contributordoi
Herpesvirus-6 Infection Associated Hemophagocytic Lymphohistiocytosis - Excellent Outcome Despite Frequent Central Nervous Involvement: A Case Series Study
2025cited by 0position: contributordoi
DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.
2024cited by 15position: contributordoi
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
Blood 2024cited by 13position: middledoi
Anaplastic sarcoma of the kidney ( <i>DICER1</i> ‐sarcoma of the kidney): A report from the International Pleuropulmonary Blastoma/ <i>DICER1</i> Registry
Pediatric Blood & Cancer 2024cited by 12position: middledoi
Anaplastic sarcoma of the kidney (DICER1-sarcoma of the kidney): A report from the International Pleuropulmonary Blastoma/DICER1 Registry.
2024cited by 11position: contributordoi
Prevalence of lung cysts in adolescents and adults with a germline &lt;i&gt;DICER1&lt;/i&gt; pathogenic/likely pathogenic variant: a report from the National Institutes of Health and International Pleuropulmonary Blastoma/&lt;i&gt;DICER1&lt;/i&gt; Registry.
2024cited by 11position: contributordoi
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.
2024cited by 9position: contributordoi
Healthcare cost and utilization for chimeric antigen receptor (CAR) T-cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis.
2024cited by 7position: contributordoi
HLH Syndrome in a Community Hospital: The Challenge of an Early Diagnosis.
2024cited by 1position: contributordoi
Outcome of Infants Treated on Total Therapy for Infants with Acute Lymphoblastic Leukemia I: Results from a Non-Randomized Multi-Center Study
Blood 2023cited by 6position: middledoi
Assessing the role of positron emission tomography and bone scintigraphy in imaging of pleuropulmonary blastoma (PPB): A report from the International PPB/DICER1 Registry.
2023cited by 5position: contributordoi
Health-related quality of life in children and adolescents with pleuropulmonary blastoma: A report from the International PPB/DICER1 Registry.
2023cited by 2position: contributordoi
Healthcare Cost and Utilization for Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis
2023cited by 0position: contributordoi
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
Journal of Clinical Oncology 2022cited by 142position: middledoi
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
2022cited by 109position: contributordoi
Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma (study T2008‐002 NECTAR)
Pediatric Blood & Cancer 2022cited by 27position: middledoi
Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/<i>DICER1</i> Registry
Journal of Clinical Oncology 2022cited by 23position: lastdoi
Type I and Ir pleuropulmonary blastoma (PPB): A report from the International PPB/<i>DICER1</i> Registry
Cancer 2022cited by 22position: middledoi
Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
2022cited by 15position: contributordoi
A natural history study of nitrous oxide versus propofol-assisted intrathecal therapy in the treatment of acute lymphoblastic leukemia.
2022cited by 1position: contributordoi
Thoracic Sertoli-Leydig cell tumor: An alternative type of pleuropulmonary blastoma associated with DICER1 variation.
2021cited by 6position: contributordoi
Delayed diagnosis of Griscelli syndrome type 2 with compound heterozygote <i>RAB27A</i> variants presenting with pulmonary failure.
2021cited by 5position: contributordoi
A Natural History Study of Nitrous Oxide versus Propofol-Assisted Intrathecal Therapy in the Treatment of Acute Lymphoblastic Leukemia
2021cited by 0position: contributordoi
Pleuropulmonary blastoma-like peritoneal sarcoma: a newly described malignancy associated with biallelic DICER1 pathogenic variation
Modern Pathology 2020cited by 42position: middledoi
A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies
Pediatric Hematology and Oncology 2020cited by 23position: middledoi
A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies.
2020cited by 20position: contributordoi
Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
2020cited by 15position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 21 papers (2019–2025)Alexander T. Nelson · Beth Israel Deaconess Medical Center6 papers (2021–2025)Kris Ann Schultz · Center for Cancer and Blood Disorders6 papers (2021–2025) · 6 papers (2015–2024)D. Ashley Hill · Georgetown University6 papers (2015–2024)Kris Ann P. Schultz · Johannes Gutenberg University Mainz6 papers (2015–2024)Louis P. Dehner · Nationwide Children's Hospital6 papers (2015–2024)Douglas R. Stewart · National Cancer Institute5 papers (2015–2022)Bruce C. Bostrom · Minnesota West Community & Technical College4 papers (2019–2020)Alexander T. Nelson · University of Minnesota, Twin Cities4 papers (2020–2024)Paul S. Gaynon · Columbia University4 papers (2014–2022)Richard Sposto · Radiation Effects Research Foundation4 papers (2014–2022)John M. Goldberg · Oncor (United States)3 papers (2014–2022)Douglas R. Stewart · National Cancer Institute3 papers (2023–2025)Lane H. Miller · Emory University3 papers (2020–2021)Junne Kamihara · Hospital for Sick Children3 papers (2022–2024)Sarah G. Mitchell · Emory University3 papers (2020–2022)Leigh Marcus · National Heart Lung and Blood Institute3 papers (2014–2022)Lia Gore · The University of Texas Health Science Center at Houston3 papers (2014–2022)Lewis B. Silverman · Dana-Farber Cancer Institute3 papers (2014–2022)